查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553664

运动医学血液生物标记市场规模、份额、趋势分析报告：按类型、地区、细分市场预测，2024-2030 年

Blood-based Biomarker For Sports Medicine Market Size, Share & Trends Analysis Report By Type (CK, Myoglobin, Lactate, WBC, Urea, CRP), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 105 Pages | 商品交期: 2-10个工作天内

价格

运动医学市场成长和趋势的血液生物标记：

Grand View Research, Inc.的最新报告显示，到2030年，运动医学用血液生物标记的全球市场规模预计将达到11.6亿美元，2024年至2030年的复合年增长率为6.7%，预计将扩大。

推动该市场的关键因素是对个人化健康的日益关注、生物标记技术的进步以及对准确表现和恢復评估的需求不断增加。此外，人们对运动相关伤害的认识不断提高以及对精确诊断的需求也有助于市场的成长和创新。

日益关注研发和增加对运动医学的投资是市场扩张的主要动力。随着运动医学领域的发展，人们越来越关注透过先进的生物标记来了解运动员复杂的生理反应。对运动医学研究的投资正在推动以血液为基础的生物标记技术的重大进步。公司和研究机构正在大力投资开发高通量筛检方法和先进的资料分析，以改善生物标记的检测和解释。公共和私人组织不断增加的投资进一步推动了运动医学领域对先进生物标记的需求。

此外，还研究了生物标记的可预测性，以主动预测受伤风险。根据发表在《生理学前沿》上的一项研究，高级研究重点关注氧化压力和发炎的生物标誌物，以预测损伤易感性。这种预测能力对于预防策略很有价值，可以帮助运动员采取主动措施避免受伤。因此，运动医学中基于血液的生物标记市场正在经历显着增长。

运动医学市场血液生物标记报告亮点

  • 肌酸激酶 (CK) 细分市场在 2023 年占据最大收益占有率，达到 18.0%。人们对伤害预防和管理的日益关注，以及运动员和运动团队对防止过度训练和优化恢復的重要性的认识不断提高，推动了对 CK 测试的需求。
  • 从事运动医学血液生物标记市场的主要企业包括 Abbott、BIOMERIEUX、F. Hoffmann-La Roche Ltd.、ARUP Laboratories、Siemens Healthineers AG 和 RayBiotech, Inc.。此外，新兴市场正在见证新参与企业推出创新新产品，以及主要市场参与企业之间建立策略联盟来开发新产品。
  • 2023 年 3 月，雅培获得美国FDA 批准首个商业化 TBI 血液检测，使其在美国医院广泛使用。此测试可检测血液中的两种生物标记物，当它们含量较高时，与脑损伤密切相关。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章运动医学市场变数、趋势和范围的血液生物标记

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 运动医学基于血液的生物标记市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 管道分析

第四章运动医学血液生物标记市场：按类型估计和趋势分析

  • 全球运动医学血液生物标记市场：按类型分類的仪表板
  • 全球运动医学血液生物标记市场：按类型的变异分析
  • 全球运动医学血液生物标记市场：按类型分類的收益
  • CK
  • 肌红蛋白
  • 乳酸
  • 白血球计数
  • 尿素
  • ＣＲＰ
  • 脂质和蛋白质氢过氧化物
  • IL-6
  • 其他的

第五章运动医学血液生物标记市场：按类型和地区分類的估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第六章 竞争状况

  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
    • Abbott
    • BIOMERIEUX
    • F. Hoffmann-La Roche Ltd.
    • ARUP Laboratories
    • Siemens Healthineers AG
    • RayBiotech, Inc.
    • Thermo Fisher Scientific, Inc.
    • Bio-Rad Laboratories, Inc.
    • Beckman Coulter, Inc.
    • Randox Laboratories Ltd.
Product Code: GVR-4-68040-436-1

Blood-Based Biomarker For Sports Medicine Market Growth & Trends:

The global blood-based biomarker for sports medicine market size is anticipated to reach USD 1.16 billion by 2030 and is anticipated to expand at a CAGR of 6.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving this market are the increasing focus on personalized health, advancements in biomarker technology, and growing demand for accurate performance & recovery assessments. Moreover, rising awareness of sports-related injuries and the need for precise diagnostics also contribute to market growth & innovation.

The growing emphasis on R&D and rising investments in sports medicine are significantly driving the market expansion. As the sports medicine field evolves, there is an increasing focus on understanding the complex physiological responses of athletes through advanced biomarkers. Investment in sports medicine research is promoting significant advancements in blood-based biomarker technologies. Companies and research institutions are investing heavily in developing high-throughput screening methods and advanced data analytics to improve biomarker detection and interpretation. The growing investment from public and private organizations further propels the demand for advanced biomarkers in sports medicine.

Moreover, the predictive potential of biomarkers is also being investigated to predict injury risks before they occur. According to research published in Frontiers in Physiology, advanced research focuses on oxidative stress and inflammation biomarkers to predict injury susceptibility. This predictive capability is valuable for preventive strategies, helping athletes avoid injuries through proactive measures. As a result, the market for blood-based biomarkers in sports medicine is experiencing significant growth.

Blood-Based Biomarker For Sports Medicine Market Report Highlights:

  • The creatine kinase (CK) segment accounted for the largest revenue share at 18.0% in 2023. The demand for CK testing is driven by the increasing focus on injury prevention and management and increasing awareness among athletes & sports teams about the importance of preventing overtraining and optimizing recovery
  • Some of the key players operating in the blood-based biomarkers for sports medicine market are Abbott, BIOMERIEUX, F. Hoffmann-La Roche Ltd., ARUP Laboratories, Siemens Healthineers AG, and RayBiotech, Inc. Furthermore, the market is witnessing the emergence of new and innovative products from new players, as well as strategic partnerships among key market players to develop new offerings
  • In March 2023, Abbott obtained clearance from the U.S. FDA for the first commercially available laboratory blood test for TBI, allowing it to be widely accessible in U.S. hospitals. The test detects two biomarkers in the blood, which, when present at elevated levels, are strongly associated with brain injury

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Blood-based Biomarker for Sports Medicine Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing Demand for Personalized Medicine
      • 3.2.1.2. Increased Focus on Injury Prevention and Recovery
      • 3.2.1.3. Growing R&D and Rising Investments in Sports Medicine s
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Regulatory Challenges and Lack of Awareness & Standardization
  • 3.3. Blood-based Biomarker for Sports Medicine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Blood-based Biomarker for Sports Medicine Market: Type Estimates & Trend Analysis

  • 4.1. Global Blood-based Biomarker for Sports Medicine Market: Type Dashboard
  • 4.2. Global Blood-based Biomarker for Sports Medicine Market: Type Movement Analysis
  • 4.3. Global Blood-based Biomarker for Sports Medicine Market by Type, Revenue
  • 4.4. CK
    • 4.4.1. CK market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Myoglobin
    • 4.5.1. Myoglobin market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6. Lactate
    • 4.6.1. Lactate market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.7. WBC
    • 4.7.1. WBC market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.8. Urea
    • 4.8.1. Urea market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.9. CRP
    • 4.9.1. CRP market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.10. Lipid and Protein Hydroperoxides
    • 4.10.1. Lipid and protein hydroperoxides market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.11. IL-6
    • 4.11.1. IL-6 market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.12. Others
    • 4.12.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Blood-based Biomarker for Sports Medicine Market: Regional Estimates & Trend Analysis by Type

  • 5.1. Regional Dashboard
  • 5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.3. North America
    • 5.3.1. U.S.
      • 5.3.1.1. Key country dynamics
      • 5.3.1.2. Regulatory framework/ reimbursement structure
      • 5.3.1.3. Competitive scenario
      • 5.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.3.2. Canada
      • 5.3.2.1. Key country dynamics
      • 5.3.2.2. Regulatory framework/ reimbursement structure
      • 5.3.2.3. Competitive scenario
      • 5.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.3.3. Mexico
      • 5.3.3.1. Key country dynamics
      • 5.3.3.2. Regulatory framework/ reimbursement structure
      • 5.3.3.3. Competitive scenario
      • 5.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Key country dynamics
      • 5.4.1.2. Regulatory framework/ reimbursement structure
      • 5.4.1.3. Competitive scenario
      • 5.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Key country dynamics
      • 5.4.2.2. Regulatory framework/ reimbursement structure
      • 5.4.2.3. Competitive scenario
      • 5.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.3. France
      • 5.4.3.1. Key country dynamics
      • 5.4.3.2. Regulatory framework/ reimbursement structure
      • 5.4.3.3. Competitive scenario
      • 5.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Key country dynamics
      • 5.4.4.2. Regulatory framework/ reimbursement structure
      • 5.4.4.3. Competitive scenario
      • 5.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Key country dynamics
      • 5.4.5.2. Regulatory framework/ reimbursement structure
      • 5.4.5.3. Competitive scenario
      • 5.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.6. Norway
      • 5.4.6.1. Key country dynamics
      • 5.4.6.2. Regulatory framework/ reimbursement structure
      • 5.4.6.3. Competitive scenario
      • 5.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.7. Sweden
      • 5.4.7.1. Key country dynamics
      • 5.4.7.2. Regulatory framework/ reimbursement structure
      • 5.4.7.3. Competitive scenario
      • 5.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.8. Denmark
      • 5.4.8.1. Key country dynamics
      • 5.4.8.2. Regulatory framework/ reimbursement structure
      • 5.4.8.3. Competitive scenario
      • 5.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Key country dynamics
      • 5.5.1.2. Regulatory framework/ reimbursement structure
      • 5.5.1.3. Competitive scenario
      • 5.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.2. China
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework/ reimbursement structure
      • 5.5.2.3. Competitive scenario
      • 5.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.3. India
      • 5.5.3.1. Key country dynamics
      • 5.5.3.2. Regulatory framework/ reimbursement structure
      • 5.5.3.3. Competitive scenario
      • 5.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Key country dynamics
      • 5.5.4.2. Regulatory framework/ reimbursement structure
      • 5.5.4.3. Competitive scenario
      • 5.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.5. New Zealand
      • 5.5.5.1. Key country dynamics
      • 5.5.5.2. Regulatory framework/ reimbursement structure
      • 5.5.5.3. Competitive scenario
      • 5.5.5.4. New Zealand market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.6. Taiwan
      • 5.5.6.1. Key country dynamics
      • 5.5.6.2. Regulatory framework/ reimbursement structure
      • 5.5.6.3. Competitive scenario
      • 5.5.6.4. Taiwan market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.7. Hong Kong
      • 5.5.7.1. Key country dynamics
      • 5.5.7.2. Regulatory framework/ reimbursement structure
      • 5.5.7.3. Competitive scenario
      • 5.5.7.4. Hong Kong market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.8. Singapore
      • 5.5.8.1. Key country dynamics
      • 5.5.8.2. Regulatory framework/ reimbursement structure
      • 5.5.8.3. Competitive scenario
      • 5.5.8.4. Singapore market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.9. Thailand
      • 5.5.9.1. Key country dynamics
      • 5.5.9.2. Regulatory framework/ reimbursement structure
      • 5.5.9.3. Competitive scenario
      • 5.5.9.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.10. Vietnam
      • 5.5.10.1. Key country dynamics
      • 5.5.10.2. Regulatory framework/ reimbursement structure
      • 5.5.10.3. Competitive scenario
      • 5.5.10.4. Vietnam market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Key country dynamics
      • 5.6.1.2. Regulatory framework/ reimbursement structure
      • 5.6.1.3. Competitive scenario
      • 5.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.6.2. Argentina
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework/ reimbursement structure
      • 5.6.2.3. Competitive scenario
      • 5.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.6.3. Chile
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Regulatory framework/ reimbursement structure
      • 5.6.3.3. Competitive scenario
      • 5.6.3.4. Chile market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7. MEA
    • 5.7.1. South Africa
      • 5.7.1.1. Key country dynamics
      • 5.7.1.2. Regulatory framework/ reimbursement structure
      • 5.7.1.3. Competitive scenario
      • 5.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.2. Saudi Arabia
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework/ reimbursement structure
      • 5.7.2.3. Competitive scenario
      • 5.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework/ reimbursement structure
      • 5.7.3.3. Competitive scenario
      • 5.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.4. Egypt
      • 5.7.4.1. Key country dynamics
      • 5.7.4.2. Regulatory framework/ reimbursement structure
      • 5.7.4.3. Competitive scenario
      • 5.7.4.4. Egypt market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.5. Qatar
      • 5.7.5.1. Key country dynamics
      • 5.7.5.2. Regulatory framework/ reimbursement structure
      • 5.7.5.3. Competitive scenario
      • 5.7.5.4. Qatar market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company/Competition Categorization
  • 6.2. Vendor Landscape
    • 6.2.1. List of key distributors and channel partners
    • 6.2.2. Key customers
    • 6.2.3. Key company market share analysis, 2023
    • 6.2.4. Abbott
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. BIOMERIEUX
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. F. Hoffmann-La Roche Ltd.
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. ARUP Laboratories
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
    • 6.2.8. Siemens Healthineers AG
      • 6.2.8.1. Company overview
      • 6.2.8.2. Financial performance
      • 6.2.8.3. Product benchmarking
      • 6.2.8.4. Strategic initiatives
    • 6.2.9. RayBiotech, Inc.
      • 6.2.9.1. Company overview
      • 6.2.9.2. Financial performance
      • 6.2.9.3. Product benchmarking
      • 6.2.9.4. Strategic initiatives
    • 6.2.10. Thermo Fisher Scientific, Inc.
      • 6.2.10.1. Company overview
      • 6.2.10.2. Financial performance
      • 6.2.10.3. Product benchmarking
      • 6.2.10.4. Strategic initiatives
    • 6.2.11. Bio-Rad Laboratories, Inc.
      • 6.2.11.1. Company overview
      • 6.2.11.2. Financial performance
      • 6.2.11.3. Product benchmarking
      • 6.2.11.4. Strategic initiatives
    • 6.2.12. Beckman Coulter, Inc.
      • 6.2.12.1. Company overview
      • 6.2.12.2. Financial performance
      • 6.2.12.3. Product benchmarking
      • 6.2.12.4. Strategic initiatives
    • 6.2.13. Randox Laboratories Ltd.
      • 6.2.13.1. Company overview
      • 6.2.13.2. Financial performance
      • 6.2.13.3. Product benchmarking
      • 6.2.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America blood-based biomarker for sports medicine market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 4 U.S. blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 5 Canada blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 6 Mexico blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 7 Europe blood-based biomarker for sports medicine market, by region, 2018 - 2030 (USD Million)
  • Table 8 Europe blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 9 Germany blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 10 UK blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 11 France blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 12 Italy blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 13 Spain blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 14 Denmark blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 15 Sweden blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 16 Norway blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific blood-based biomarker for sports medicine market, by region, 2018 - 2030 (USD Million)
  • Table 18 Asia Pacific blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 19 China blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 20 New Zealand blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 21 Taiwan blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 22 Hong Kong blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 23 Singapore blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 24 Thailand blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 25 Vietnam blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 26 Japan blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 27 India blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 28 South Korea blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 29 Australia blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 30 New Zealand blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 31 Latin America blood-based biomarker for sports medicine market, by region, 2018 - 2030 (USD Million)
  • Table 32 Latin America blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 33 Brazil blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 34 Argentina blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 35 Chile blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 36 MEA blood-based biomarker for sports medicine market, by region, 2018 - 2030 (USD Million)
  • Table 37 MEA blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 38 South Africa blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 39 Saudi Arabia blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 40 UAE blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 41 Egypt blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 42 Qatar blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Blood-based biomarker for sports medicine market: market outlook
  • Fig. 14 Blood-based biomarker for sports medicine competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Blood-based biomarker for sports medicine market driver impact
  • Fig. 18 Blood-based biomarker for sports medicine market restraint impact
  • Fig. 19 Blood-based biomarker for sports medicine market: Type movement analysis
  • Fig. 20 Blood-based Biomarker for Sports Medicine market: Type outlook and key takeaways
  • Fig. 21 CK market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Myoglobin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Lactate market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 WBC market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Urea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 CRP market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Lipid and protein hydroperoxides market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 IL-6 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Global blood-based biomarker for sports medicine market: Regional movement analysis
  • Fig. 31 Global blood-based biomarker for sports medicine market: Regional outlook and key takeaways
  • Fig. 32 Global blood-based biomarker for sports medicine market share and leading players
  • Fig. 33 North America, by country
  • Fig. 34 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. key country dynamics
  • Fig. 36 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Canada key country dynamics
  • Fig. 38 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico key country dynamics
  • Fig. 40 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 UK key country dynamics
  • Fig. 43 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Germany key country dynamics
  • Fig. 45 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 France key country dynamics
  • Fig. 47 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Italy key country dynamics
  • Fig. 49 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Spain key country dynamics
  • Fig. 51 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Denmark key country dynamics
  • Fig. 53 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Sweden key country dynamics
  • Fig. 55 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Norway key country dynamics
  • Fig. 57 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 China key country dynamics
  • Fig. 60 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Japan key country dynamics
  • Fig. 62 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 India key country dynamics
  • Fig. 64 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 New Zealand key country dynamics
  • Fig. 66 New Zealand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea key country dynamics
  • Fig. 68 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Australia key country dynamics
  • Fig. 70 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Taiwan key country dynamics
  • Fig. 72 Taiwan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Hong Kong key country dynamics
  • Fig. 74 Hong Kong market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Singapore key country dynamics
  • Fig. 76 Singapore market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Thailand key country dynamics
  • Fig. 78 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Vietnam key country dynamics
  • Fig. 80 Vietnam market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Brazil key country dynamics
  • Fig. 83 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Argentina key country dynamics
  • Fig. 85 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Chile key country dynamics
  • Fig. 87 Chile market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 South Africa key country dynamics
  • Fig. 90 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Saudi Arabia key country dynamics
  • Fig. 92 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 UAE key country dynamics
  • Fig. 94 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Egypt key country dynamics
  • Fig. 96 Egypt market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Qatar key country dynamics
  • Fig. 98 Qatar market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Market share of key market players- blood-based biomarker for sports medicine market